Despite a temporary halt of an experimental spinal cord implant trial following a patient death, InVivo Therapeutics is doubling down and focusing its financial resources on the treatment by initiating a strategic restructuring that includes cutting nearly 40 percent of its workforce.
The U.S. FDA turned down Acorda Therapeutics’ New Drug Application for Inbrija, which was being evaluated for OFF periods in Parkinson’s disease.
AstraZeneca is to receive up to $400 million from Takeda after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson’s disease.
PACIFIC Communications, the West Coast’s largest healthcare communications agency, announced the return of Associate Creative Director/Copy Kent Sewell.
A large study of a new type of cholesterol medicine from Merck & Co. Inc. found it cut the risk of heart attack and death by a modest 9 percent, while causing a build up of the drug in fat tissue, leaving its commercial future uncertain.
Outcome Health, which provides health intelligence in moments of care to improve patient outcomes, announced the hiring of its first Chief Engineering Officer, Nandini Ramani.
Bristol-Myers Squibb Co. and Daiichi Sankyo said they were evaluating a combination of Bristol-Myers’ immuno-oncology drug, Opdivo with the Japanese company’s experimental drug in patients with breast and bladder cancers.
The U.S. FDA is stepping up efforts to better regulate an emerging field of medicine that holds significant promise for curing some of the most troubling diseases by using the body’s own cells.
AstraZeneca forged a research collaboration with Boston-based Berg, a specialist in artificial intelligence for drug hunting.
Gilead Sciences agreed to buy Kite Pharma in a nearly $12 billion deal as it looks to replace flagging sales from hepatitis C drugs via cancer immunotherapies.
CSL Ltd. bought Tucson, Ariz.-based Calimmune for $91 million upfront and up to $325 million in performance-based milestones.
An anti-inflammatory drug developed for cardiac patients has an exciting, yet unintended side effect – possible prevention of lung cancer.
Bayer and Johnson & Johnson’s blockbuster clot prevention drug Xarelto was shown to cut the risk of potentially deadly strokes and heart attacks in patients with severe atherosclerosis by 24 percent, raising the prospects of billions more in sales.
Surgeons re-attached a woman’s arms after they were severed by a train, a rare operation and a first in France in that both limbs were worked on at the same time.
The FDA approved an expanded use of Novo Nordisk’s diabetes drug Victoza to reduce the risk of cardiovascular events such as heart attack and stroke.
Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA’s role in ensuring Americans have access to clear and consistent calorie and nutrition information
“As a doctor, father and the head of the U.S. Food & Drug Administration, I believe that everyone is entitled to the information they need to make informed decisions about the food they eat. We serve as the nation’s expert on food labeling, which is why Congress entrusted us with the responsibility of crafting predictable, uniform federal standards that will benefit the health of families across America by ensuring access to essential calorie and nutrition information on food and menu labels.”
Shares of beleaguered Dimension Therapeutics Inc. soared more than 160 percent in premarket trading after gene therapy company Regenxbio Inc. announced its acquisition via an all-stock deal.
The U.S. Food and Drug Administration granted its Breakthrough Therapy Designation to a drug that has been available to lymphoma patients in Japan for several years.
Pfizer reportedly chose a site for the company’s new headquarters, the as-yet constructed Manhattan skyscraper The Spiral.
A biosimilar version of AbbVie Inc.’s blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc. and Samsung Biologics, was approved by EU regulators.